Apelin and insulin resistance: Another arrow for the quiver?

Journal of Diabetes

Volumn 3, Issue 3, 2011, Pages 225-231

  Xu, Shiming ^a   Tsao, Philip S ^a   Yue, Patrick ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apelin; Diabetes; Glucose; Insulin resistance; Lipolysis

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; APELIN; CATECHOLAMINE; FATTY ACID; G PROTEIN COUPLED RECEPTOR; PEPTIDE HORMONE;

GLUCOSE UTILIZATION; INSULIN RELEASE; INSULIN RESISTANCE; LIPID METABOLISM; LIPOLYSIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ADIPOSE TISSUE; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOLYSIS; MODELS, BIOLOGICAL; OBESITY;

EID: 80051824524     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/j.1753-0407.2011.00132.x     Document Type: Review

References (66)

1. Tatemoto K, Hosoya M, Habata Y et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998; 251: 471-6.
2. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States. 2011; Availabe from: (accessed 7 February 2011).
3. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 1988; 37: 1020-4.
4. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004; 110: 1245-50.
5. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: Two growing epidemics with a potential link. Cancer. 2009; 115: 5651-61.
6. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: An update. Dig Dis. 2010; 28: 645-56.
7. Porto LA, Lora KJ, Soares JC, Costa LO. Metabolic syndrome is an independent risk factor for breast cancer. Arch Gynecol Obstet. 2011; doi:.
8. Siddiqui AA. Metabolic syndrome and its association with colorectal cancer: A review. Am J Med Sci. 2011; 341: 227-31.
9. O'Dowd BF, Heiber M, Chan A et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993; 136: 355-60.
10. Masri B, Lahlou H, Mazarguil H, Knibiehler B, Audigier Y. Apelin (65-77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein. Biochem Biophys Res Commun. 2002; 290: 539-45.
11. Szokodi I, Tavi P, Foldes G et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res. 2002; 91: 434-40.
12. Lee DK, Cheng R, Nguyen T et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000; 74: 34-41.
13. Tatemoto K, Takayama K, Zou MX et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001; 99: 87-92.
14. Japp AG, Cruden NL, Amer DA et al. Vascular effects of apelin in vivo in man. J Am Coll Cardiol. 2008; 52: 908-13.
15. Vickers C, Hales P, Kaushik V et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002; 277: 14838-43.
16. Mesmin C, Dubois M, Becher F, Fenaille F, Ezan E. Liquid chromatography/tandem mass spectrometry assay for the absolute quantification of the expected circulating apelin peptides in human plasma. Rapid Commun Mass Spectrom. 2010; 24: 2875-84.
17. Japp AG, Cruden NL, Barnes G et al. Acute cardiovascular effects of apelin in humans: Potential role in patients with chronic heart failure. Circulation. 2010; 121: 1818-27.
18. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010; 62: 331-42.
19. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005; 126: 233-40.
20. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 2004; 118: 119-25.
21. Glassford AJ, Yue P, Sheikh AY et al. HIF-1 regulates hypoxia- and insulin-induced expression of apelin in adipocytes. Am J Physiol Endocrinol Metab. 2007; 293: E1590-6.
22. Boucher J, Masri B, Daviaud D et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology. 2005; 146: 1764-71.
23. Wei L, Hou X, Tatemoto K. Regulation of apelin mRNA expression by insulin and glucocorticoids in mouse 3T3-L1 adipocytes. Regul Pept. 2005; 132: 27-32.
24. Castan-Laurell I, Boucher J, Dray C, Daviaud D, Guigne C, Valet P. Apelin, a novel adipokine over-produced in obesity: Friend or foe? Mol Cell Endocrinol. 2005; 245: 7-9.
25. Li L, Yang G, Li Q et al. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and Type 2 diabetic subjects. Exp Clin Endocrinol Diabetes. 2006; 114: 544-8.
26. Soriguer F, Garrido-Sanchez L, Garcia-Serrano S et al. Apelin levels are increased in morbidly obese subjects with Type 2 diabetes mellitus. Obes Surg. 2009; 19: 1574-80.
27. Daviaud D, Boucher J, Gesta S et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J. 2006; 20: 1528-30.
28. Dray C, Debard C, Jager J et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of Type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab. 2010; 298: E1161-9.
29. Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008; 116: 289-92.
30. Zhang Y, Shen C, Li X et al. Low plasma apelin in newly diagnosed Type 2 diabetes in Chinese people. Diabetes Care. 2009; 32: e150.
31. Hata J, Matsuda K, Ninomiya T et al. Functional SNP in an Sp1-binding site of AGTRL1 gene is associated with susceptibility to brain infarction. Hum Mol Genet. 2007; 16: 630-9.
32. Sarzani R, Forleo C, Pietrucci F et al. The 212A variant of the APJ receptor gene for the endogenous inotrope apelin is associated with slower heart failure progression in idiopathic dilated cardiomyopathy. J Card Fail. 2007; 13: 521-9.
33. Li WW, Niu WQ, Zhang Y, Wu S, Gao PJ, Zhu DL. Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese. J Hypertens. 2009; 27: 1194-201.
34. Zhao Q, Gu D, Kelly TN et al. Association of genetic variants in the apelin-APJ system and ACE2 with blood pressure responses to potassium supplementation: The GenSalt study. Am J Hypertens. 2010; 23: 606-13.
35. Zhao Q, Hixson JE, Rao DC et al. Genetic variants in the apelin system and blood pressure responses to dietary sodium interventions: A family-based association study. J Hypertens. 2010; 28: 756-63.
36. Niu W, Wu S, Zhang Y et al. Validation of genetic association in apelin-AGTRL1 system with hypertension in a larger Han Chinese population. J Hypertens. 2010; 28: 1854-61.
37. Zhang R, Hu C, Wang CR et al. Association of apelin genetic variants with Type 2 diabetes and related clinical features in Chinese Hans. Chin Med J. 2009; 122: 1273-6.
38. Guo L, Li Q, Wang W et al. Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B. Endocr Res. 2009; 34: 142-54.
39. Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept. 2005; 131: 12-7.
40. Higuchi K, Masaki T, Gotoh K et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007; 148: 2690-7.
41. Dray C, Knauf C, Daviaud D et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab. 2008; 8: 437-45.
42. Yue P, Jin H, Aillaud M et al. Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab. 2010; 298: E59-67.
43. Attane C, Daviaud D, Dray C et al. Apelin stimulates glucose uptake but not lipolysis in human adipose tissue ex vivo. J Mol Endocrinol. 2011; 46: 21-8.
44. iα2. Nature. 1996; 379: 840-4.
45. αi2in vivo mimics insulin action. J Mol Med. 1997; 75: 283-9.
46. Yue P, Jin H, Xu S et al. Apelin decreases lipolysis via G(q), G(i), and AMPK-dependent mechanisms. Endocrinology. 2011; 152: 59-68.
47. Sgourakis NG, Bagos PG, Hamodrakas SJ. Prediction of the coupling specificity of GPCRs to four families of G-proteins using hidden Markov models and artificial neural networks. Bioinformatics. 2005; 21: 4101-6.
48. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol Rev. 2009; 89: 1025-78.
49. Moule SK, Denton RM. The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett. 1998; 439: 287-90.
50. Park H, Kaushik VK, Constant S et al. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem. 2002; 277: 32571-7.
51. 2+/calmodulin-dependent protein kinase kinase-dependent pathways. J Biol Chem. 2009; 284: 22426-35.
52. Masri B, Morin N, Cornu M, Knibiehler B, Audigier Y. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J. 2004; 18: 1909-11.
53. Chun HJ, Ali ZA, Kojima Y et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest. 2008; 118: 3343-54.
54. Zhu S, Sun F, Li W et al. Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Mol Cell Biochem. 2011; doi:.
55. Jia YX, Pan CS, Zhang J et al. Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept. 2006; 133: 147-54.
56. Leeper NJ, Tedesco MM, Kojima Y et al. Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. Am J Physiol Heart Circ Physiol. 2009; 296: H1329-35.
57. Heinonen MV, Purhonen AK, Miettinen P et al. Apelin, orexin-A and leptin plasma levels in morbid obesity and effect of gastric banding. Regul Pept. 2005; 130: 7-13.
58. Castan-Laurell I, Vitkova M, Daviaud D et al. Effect of hypocaloric diet-induced weight loss in obese women on plasma apelin and adipose tissue expression of apelin and APJ. Eur J Endocrinol. 2008; 158: 905-10.
59. Thiebaud D, DeFronzo RA, Jacot E et al. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism. 1982; 31: 1128-36.
60. Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999; 103: 253-9.
61. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest. 1983; 72: 1737-47.
62. Bajaj M, Suraamornkul S, Romanelli A et al. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in Type 2 diabetic patients. Diabetes. 2005; 54: 3148-53.
63. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000; 106: 171-6.
64. Valle A, Hoggard N, Adams AC, Roca P, Speakman JR. Chronic central administration of apelin-13 over 10 days increases food intake, body weight, locomotor activity and body temperature in C57BL/6 mice. J Neuroendocrinol. 2008; 20: 79-84.
65. Clarke KJ, Whitaker KW, Reyes TM. Diminished metabolic responses to centrally-administered apelin-13 in diet-induced obese rats fed a high-fat diet. J Neuroendocrinol. 2009; 21: 83-9.
66. Frier BC, Williams DB, Wright DC. The effects of apelin treatment on skeletal muscle mitochondrial content. Am J Physiol Regul Integr Comp Physiol. 2009; 297: R1761-8.